{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T06:08:34Z","timestamp":1790402914910,"version":"4.1.0"},"reference-count":101,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T00:00:00Z","timestamp":1794614400000},"content-version":"am","delay-in-days":378,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.blre.2025.101319","type":"journal-article","created":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T11:14:49Z","timestamp":1750677289000},"page":"101319","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Iron chelation therapy in myelodysplastic syndromes and allogeneic hematopoietic cell transplantation, a delicate balance"],"prefix":"10.1016","volume":"74","author":[{"given":"Fieke W.","family":"Hoff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduard","family":"Schulz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Pavletic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Mina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"14","key":"10.1016\/j.blre.2025.101319_bb0005","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1056\/NEJMra1904794","article-title":"Myelodysplastic syndromes","volume":"383","author":"Cazzola","year":"2020","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.blre.2025.101319_bb0010","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1001\/jama.2022.14578","article-title":"Diagnosis and treatment of myelodysplastic syndromes: a review","volume":"328","author":"Sekeres","year":"2022","journal-title":"JAMA"},{"issue":"16","key":"10.1016\/j.blre.2025.101319_bb0015","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1182\/blood.2021011045","article-title":"Ineffective erythropoiesis and its treatment","volume":"139","author":"Cazzola","year":"2022","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.blre.2025.101319_bb0020","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/S0145-2126(98)00112-X","article-title":"Apoptosis and its role in the myelodysplastic syndromes: implications for disease natural history and treatment","volume":"22","author":"Greenberg","year":"1998","journal-title":"Leuk Res"},{"issue":"12","key":"10.1016\/j.blre.2025.101319_bb0025","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised international prognostic scoring system for myelodysplastic syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"issue":"30","key":"10.1016\/j.blre.2025.101319_bb0030","doi-asserted-by":"crossref","first-page":"7594","DOI":"10.1200\/JCO.2005.01.7038","article-title":"Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making","volume":"23","author":"Malcovati","year":"2005","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.blre.2025.101319_bb0035","doi-asserted-by":"crossref","first-page":"476","DOI":"10.3324\/haematol.2009.011429","article-title":"Prognostic impact of pre-transplantation transfusion history and secondary iron overload in patients with myelodysplastic syndrome undergoing allogeneic stem cell transplantation: a GITMO study","volume":"95","author":"Alessandrino","year":"2010","journal-title":"Haematologica"},{"issue":"10","key":"10.1016\/j.blre.2025.101319_bb0040","doi-asserted-by":"crossref","first-page":"4586","DOI":"10.1182\/blood-2006-10-054924","article-title":"Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation","volume":"109","author":"Armand","year":"2007","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.blre.2025.101319_bb0045","doi-asserted-by":"crossref","first-page":"6460","DOI":"10.1158\/1078-0432.CCR-12-1683","article-title":"MRI-based liver iron content predicts for nonrelapse mortality in MDS and AML patients undergoing allogeneic stem cell transplantation","volume":"18","author":"Wermke","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.blre.2025.101319_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(18)30036-X","article-title":"Enhanced labile plasma iron and outcome in acute myeloid leukaemia and myelodysplastic syndrome after allogeneic haemopoietic cell transplantation (ALLIVE): a prospective, multicentre, observational trial","volume":"5","author":"Wermke","year":"2018","journal-title":"Lancet Haematol"},{"issue":"4","key":"10.1016\/j.blre.2025.101319_bb0055","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1182\/blood.2023022500","article-title":"How I manage iron overload in the hematopoietic cell transplantation setting","volume":"145","author":"Angelucci","year":"2025","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.blre.2025.101319_bb0060","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1093\/jnci\/djn349","article-title":"Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys","volume":"100","author":"Sekeres","year":"2008","journal-title":"J Natl Cancer Inst"},{"issue":"10","key":"10.1016\/j.blre.2025.101319_bb0065","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1182\/blood-2018-06-857102","article-title":"Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials","volume":"133","author":"Platzbecker","year":"2019","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.blre.2025.101319_bb0070","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.hoc.2010.02.005","article-title":"Prognostic classification and risk assessment in myelodysplastic syndromes","volume":"24","author":"Cazzola","year":"2010","journal-title":"Hematol Oncol Clin North Am"},{"issue":"7","key":"10.1016\/j.blre.2025.101319_bb0075","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1038\/leu.2015.55","volume":"29","author":"Della Porta","year":"2015","journal-title":"Leukemia"},{"issue":"21","key":"10.1016\/j.blre.2025.101319_bb0080","doi-asserted-by":"crossref","first-page":"3830","DOI":"10.1182\/blood.V120.21.3830.3830","article-title":"Early mortality in 1000 newly diagnosed MDS patients with low- and Intermediate-1 risk MDS in the European Leukemianet MDS (EUMDS) registry","volume":"120","author":"de Swart","year":"2012","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.blre.2025.101319_bb0085","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.cell.2016.12.034","article-title":"A red carpet for Iron metabolism","volume":"168","author":"Muckenthaler","year":"2017","journal-title":"Cell"},{"issue":"5704","key":"10.1016\/j.blre.2025.101319_bb0090","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1126\/science.1104742","article-title":"Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization","volume":"306","author":"Nemeth","year":"2004","journal-title":"Science"},{"issue":"12","key":"10.1016\/j.blre.2025.101319_bb0095","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1056\/NEJMra1804281","article-title":"Anemia of inflammation","volume":"381","author":"Ganz","year":"2019","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.blre.2025.101319_bb0100","doi-asserted-by":"crossref","first-page":"420","DOI":"10.3324\/haematol.2012.077446","article-title":"Inappropriately low hepcidin levels in patients with myelodysplastic syndrome carrying a somatic mutation of SF3B1","volume":"98","author":"Ambaglio","year":"2013","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.blre.2025.101319_bb0105","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0023109","article-title":"Hepcidin levels and their determinants in different types of myelodysplastic syndromes","volume":"6","author":"Santini","year":"2011","journal-title":"PloS One"},{"key":"10.1016\/j.blre.2025.101319_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2020.106354","article-title":"Iron overload regulate the cytokine of mesenchymal stromal cells through ROS\/HIF-1alpha pathway in myelodysplastic syndromes","volume":"93","author":"Hu","year":"2020","journal-title":"Leuk Res"},{"key":"10.1016\/j.blre.2025.101319_bb0115","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1182\/bloodadvances.2024014283","article-title":"Ferritin outperforms other biomarkers in predicting bone marrow Iron Stores in Hematological Patients","volume":"9","author":"Lahtiharju","year":"2025","journal-title":"Blood Adv"},{"issue":"10","key":"10.1016\/j.blre.2025.101319_bb0120","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.3324\/haematol.2018.193128","article-title":"Iron overload impairs normal hematopoietic stem and progenitor cells through reactive oxygen species and shortens survival in myelodysplastic syndrome mice","volume":"103","author":"Jin","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2025.101319_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2021.103367","article-title":"Iron overload-induced oxidative stress in myelodysplastic syndromes and its cellular sequelae","volume":"163","author":"Kim","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"10.1016\/j.blre.2025.101319_bb0130","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1182\/asheducation-2014.1.210","article-title":"Guidelines for quantifying iron overload","volume":"2014","author":"Wood","year":"2014","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"4","key":"10.1016\/j.blre.2025.101319_bb0135","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/ajh.23650","article-title":"Ferritin trends do not predict changes in total body iron in patients with transfusional iron overload","volume":"89","author":"Puliyel","year":"2014","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.blre.2025.101319_bb0140","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1046\/j.1365-2141.2000.02298.x","article-title":"Hepatic iron concentration combined with long-term monitoring of serum ferritin to predict complications of iron overload in thalassaemia major","volume":"110","author":"Telfer","year":"2000","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.blre.2025.101319_bb0145","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1056\/NEJM200008033430503","article-title":"Hepatic iron concentration and total body iron stores in thalassemia major","volume":"343","author":"Angelucci","year":"2000","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.blre.2025.101319_bb0150","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1161\/CIR.0b013e31829b2be6","article-title":"Cardiovascular function and treatment in beta-thalassemia major: a consensus statement from the American Heart Association","volume":"128","author":"Pennell","year":"2013","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.blre.2025.101319_bb0155","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.221856","article-title":"Quantification of liver Iron overload with MRI: review and guidelines from the ESGAR and SAR","volume":"307","author":"Reeder","year":"2023","journal-title":"Radiology"},{"issue":"1","key":"10.1016\/j.blre.2025.101319_bb0160","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1148\/radiol.11110060","article-title":"Feasibility and accuracy of dual-source dual-energy CT for noninvasive determination of hepatic iron accumulation","volume":"262","author":"Joe","year":"2012","journal-title":"Radiology"},{"issue":"1","key":"10.1016\/j.blre.2025.101319_bb0165","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1148\/radiol.2015141856","article-title":"Dual-energy CT for patients suspected of having liver Iron overload: can virtual Iron content imaging accurately quantify liver Iron content?","volume":"277","author":"Luo","year":"2015","journal-title":"Radiology"},{"issue":"6","key":"10.1016\/j.blre.2025.101319_bb0170","doi-asserted-by":"crossref","first-page":"2868","DOI":"10.1007\/s00330-018-5785-4","article-title":"Dual-energy CT for liver iron quantification in patients with haematological disorders","volume":"29","author":"Werner","year":"2019","journal-title":"Eur Radiol"},{"key":"10.1016\/j.blre.2025.101319_bb0175","article-title":"Comparative study on Iron content detection by energy spectral CT and MRI in MDS patients","volume":"11","author":"Zhang","year":"2021","journal-title":"Front Oncol"},{"issue":"6","key":"10.1016\/j.blre.2025.101319_bb0180","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1111\/j.1365-2141.2011.08590.x","article-title":"Quantitative computed tomography assessment of transfusional iron overload","volume":"153","author":"Wood","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2025.101319_bb0185","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.2147\/JBM.S287876","article-title":"Prognostic factors and clinical considerations for Iron chelation therapy in myelodysplastic syndrome patients","volume":"12","author":"Parisi","year":"2021","journal-title":"J Blood Med"},{"key":"10.1016\/j.blre.2025.101319_bb0190","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.leukres.2018.09.005","article-title":"Iron overload in myelodysplastic syndromes: evidence based guidelines from the Canadian consortium on MDS","volume":"74","author":"Leitch","year":"2018","journal-title":"Leuk Res"},{"issue":"4","key":"10.1016\/j.blre.2025.101319_bb0195","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1182\/blood.2023022502","article-title":"Management of iron overload: lessons from transfusion-dependent hemoglobinopathies","volume":"145","author":"Coates","year":"2025","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.blre.2025.101319_bb0200","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s00277-011-1164-9","article-title":"Iron status and treatment modalities in transfusion-dependent patients with myelodysplastic syndromes","volume":"90","author":"Delforge","year":"2011","journal-title":"Ann Hematol"},{"issue":"2","key":"10.1016\/j.blre.2025.101319_bb0205","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s00277-009-0794-7","article-title":"Iron overload and chelation therapy in patients with low-risk myelodysplastic syndromes with transfusion requirements","volume":"89","author":"Remacha","year":"2010","journal-title":"Ann Hematol"},{"key":"10.1016\/j.blre.2025.101319_bb0210","unstructured":"Pharmaceuticals T. Deferiprone (Ferriprox) [package insert]. U.S. Food and Drug Administration website. [Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/021825s010lbl.pdf Revised November 2021. Accessed on: February 2, 2025."},{"issue":"6","key":"10.1016\/j.blre.2025.101319_bb0215","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/ejh.12300","article-title":"Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 trial)","volume":"92","author":"Angelucci","year":"2014","journal-title":"Eur J Haematol"},{"issue":"20","key":"10.1016\/j.blre.2025.101319_bb0220","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12206569","article-title":"Iron chelation in patients with myelodysplastic syndromes and myeloproliferative neoplasms-real-world data from the German noninterventional study EXCALIBUR","volume":"12","author":"Schulz","year":"2023","journal-title":"J Clin Med"},{"issue":"8","key":"10.1016\/j.blre.2025.101319_bb0225","doi-asserted-by":"crossref","first-page":"513","DOI":"10.7326\/M19-0916","article-title":"Iron chelation in transfusion-dependent patients with low- to Intermediate-1-risk myelodysplastic syndromes: a randomized trial","volume":"172","author":"Angelucci","year":"2020","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1016\/j.blre.2025.101319_bb0230","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1111\/bjh.19316","article-title":"Cardiac effects of deferasirox in transfusion-dependent patients with myelodysplastic syndromes: TELESTO study","volume":"204","author":"Sarocchi","year":"2024","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.blre.2025.101319_bb0235","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.leukres.2012.04.006","article-title":"Improved survival in MDS patients receiving iron chelation therapy - a matched pair analysis of 188 patients from the Dusseldorf MDS registry","volume":"36","author":"Neukirchen","year":"2012","journal-title":"Leuk Res"},{"issue":"5","key":"10.1016\/j.blre.2025.101319_bb0240","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1111\/bjh.13053","article-title":"The impact of chelation therapy on survival in transfusional iron overload: a meta-analysis of myelodysplastic syndrome","volume":"167","author":"Mainous","year":"2014","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.blre.2025.101319_bb0245","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/bjh.14825","article-title":"Overall survival in lower IPSS risk MDS by receipt of iron chelation therapy, adjusting for patient-related factors and measuring from time of first red blood cell transfusion dependence: an MDS-CAN analysis","volume":"179","author":"Leitch","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2025.101319_bb0250","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.critrevonc.2019.06.002","article-title":"Hematologic improvement with iron chelation therapy in myelodysplastic syndromes: clinical data, potential mechanisms, and outstanding questions","volume":"141","author":"Leitch","year":"2019","journal-title":"Crit Rev Oncol Hematol"},{"issue":"5","key":"10.1016\/j.blre.2025.101319_bb0255","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s00277-015-2341-z","article-title":"An increase in hemoglobin, platelets and white blood cells levels by iron chelation as single treatment in multitransfused patients with myelodysplastic syndromes: clinical evidences and possible biological mechanisms","volume":"94","author":"Breccia","year":"2015","journal-title":"Ann Hematol"},{"issue":"8","key":"10.1016\/j.blre.2025.101319_bb0260","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.3324\/haematol.2009.016824","article-title":"Deferasirox is a powerful NF-kappaB inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging","volume":"95","author":"Messa","year":"2010","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.blre.2025.101319_bb0265","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/j.1365-2141.1992.tb06411.x","article-title":"Desferrioxamine treatment reduces blood transfusion requirements in patients with myelodysplastic syndrome","volume":"80","author":"Jensen","year":"1992","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.blre.2025.101319_bb0270","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1046\/j.1365-2141.1996.d01-1795.x","article-title":"The effect of iron chelation on haemopoiesis in MDS patients with transfusional iron overload","volume":"94","author":"Jensen","year":"1996","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.blre.2025.101319_bb0275","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.3892\/ol.2013.1617","article-title":"Transfusion-dependent low-risk myelodysplastic patients receiving deferasirox: long-term follow-up","volume":"6","author":"Improta","year":"2013","journal-title":"Oncol Lett"},{"issue":"2","key":"10.1016\/j.blre.2025.101319_bb0280","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1159\/000158631","article-title":"Deferasirox treatment improved the hemoglobin level and decreased transfusion requirements in four patients with the myelodysplastic syndrome and primary myelofibrosis","volume":"120","author":"Messa","year":"2008","journal-title":"Acta Haematol"},{"issue":"9","key":"10.1016\/j.blre.2025.101319_bb0285","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.3324\/haematol.2011.048546","article-title":"Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes","volume":"97","author":"Gattermann","year":"2012","journal-title":"Haematologica"},{"issue":"17","key":"10.1016\/j.blre.2025.101319_bb0290","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1200\/JCO.2010.34.1222","article-title":"Deferasirox reduces serum ferritin and labile plasma iron in RBC transfusion-dependent patients with myelodysplastic syndrome","volume":"30","author":"List","year":"2012","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.blre.2025.101319_bb0295","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/ejh.12421","article-title":"Impact of pretransplant serum ferritin level on risk of invasive mold infection after allogeneic hematopoietic stem cell transplantation","volume":"94","author":"Dadwal","year":"2015","journal-title":"Eur J Haematol"},{"issue":"12","key":"10.1016\/j.blre.2025.101319_bb0300","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/bmt.2008.262","article-title":"Iron overload adversely affects outcome of allogeneic hematopoietic cell transplantation","volume":"42","author":"Pullarkat","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2025.101319_bb0305","first-page":"e1","article-title":"Oxidative stress early after hematopoietic stem cell transplant","volume":"31(3):135","author":"Cook","year":"2025","journal-title":"Transplant Cell Ther"},{"issue":"18","key":"10.1016\/j.blre.2025.101319_bb0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e37436","article-title":"Association between the pre-transplantation serum ferritin level and outcomes of hematopoietic stem cell transplantation: a systematic review and meta-analysis","volume":"10","author":"Pan","year":"2024","journal-title":"Heliyon"},{"issue":"6","key":"10.1016\/j.blre.2025.101319_bb0315","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.bbmt.2010.09.006","article-title":"Iron overload in patients with acute leukemia or MDS undergoing myeloablative stem cell transplantation","volume":"17","author":"Armand","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.blre.2025.101319_bb0320","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1159\/000187646","article-title":"Transfusion-associated iron overload as an adverse risk factor for transplantation outcome in patients undergoing reduced-intensity stem cell transplantation for myeloid malignancies","volume":"120","author":"Kim","year":"2008","journal-title":"Acta Haematol"},{"issue":"6","key":"10.1016\/j.blre.2025.101319_bb0325","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.leukres.2009.10.028","article-title":"Impact of pre-transplant serum ferritin on outcomes of patients with myelodysplastic syndromes or secondary acute myeloid leukaemia receiving reduced intensity conditioning allogeneic haematopoietic stem cell transplantation","volume":"34","author":"Lim","year":"2010","journal-title":"Leuk Res"},{"issue":"2","key":"10.1016\/j.blre.2025.101319_bb0330","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.bbmt.2008.11.012","article-title":"Influence of pretransplantation serum ferritin on nonrelapse mortality after myeloablative and nonmyeloablative allogeneic hematopoietic stem cell transplantation","volume":"15","author":"Kataoka","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"10.1016\/j.blre.2025.101319_bb0335","doi-asserted-by":"crossref","DOI":"10.1097\/MPH.0000000000001829","article-title":"Retrospective evaluation of relationship between Iron overload and transplantation complications in pediatric patient who underwent allogeneic stem cell transplantation due to acute leukemia and myelodysplastic syndrome","volume":"42","author":"Kupesiz","year":"2020","journal-title":"J Pediatr Hematol Oncol"},{"issue":"8","key":"10.1016\/j.blre.2025.101319_bb0340","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1038\/bmt.2009.349","article-title":"Hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation: incidence, risk factors, and outcome","volume":"45","author":"Lee","year":"2010","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"10.1016\/j.blre.2025.101319_bb0345","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1182\/blood-2009-03-212282","article-title":"Serum ferritin as risk factor for sinusoidal obstruction syndrome of the liver in patients undergoing hematopoietic stem cell transplantation","volume":"114","author":"Maradei","year":"2009","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.blre.2025.101319_bb0350","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.jtct.2021.05.003","article-title":"Pretransplantation red blood cell and platelet transfusion burden in De novo myelodysplastic syndrome undergoing allogeneic transplantation","volume":"27","author":"Konuma","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"6","key":"10.1016\/j.blre.2025.101319_bb0355","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1055\/s-0028-1086030","article-title":"A novel element in the management of chronic granulomatous disease (CGD)? - treatment of osteomyelitis with additional hyperbaric oxygen therapy (HBO)","volume":"220","author":"Beltz","year":"2008","journal-title":"Klin Padiatr"},{"issue":"10","key":"10.1016\/j.blre.2025.101319_bb0360","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1080\/10428194.2019.1594215","article-title":"A prospective non-interventional study on the impact of transfusion burden and related iron toxicity on outcome in myelodysplastic syndromes undergoing allogeneic hematopoietic cell transplantation","volume":"60","author":"Cremers","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"10.1016\/j.blre.2025.101319_bb0365","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1007\/s00277-016-2802-z","article-title":"Prognostic pre-transplant factors in myelodysplastic syndromes primarily treated by high dose allogeneic hematopoietic stem cell transplantation: a retrospective study of the MDS subcommittee of the CMWP of the EBMT","volume":"95","author":"Cremers","year":"2016","journal-title":"Ann Hematol"},{"issue":"8","key":"10.1016\/j.blre.2025.101319_bb0370","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1038\/s41409-024-02297-0","article-title":"Prognostic impact of the conditioning intensity on outcomes after allogeneic transplantation for MDS with low blasts: a nationwide retrospective study by the adult MDS working group of the Japan Society for Transplantation and Cellular Therapy","volume":"59","author":"Itonaga","year":"2024","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"10.1016\/j.blre.2025.101319_bb0375","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1007\/s00277-012-1428-z","article-title":"The prognostic role of hemochromatosis H63D allele in allogeneic hematopoietic stem cell transplantation","volume":"91","author":"Sucak","year":"2012","journal-title":"Ann Hematol"},{"issue":"23","key":"10.1016\/j.blre.2025.101319_bb0380","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMra2119758","article-title":"Hemochromatosis","volume":"387","author":"Olynyk","year":"2022","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.blre.2025.101319_bb0385","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s00277-010-0901-9","article-title":"Effects of C282Y, H63D, and S65C HFE gene mutations, diet, and life-style factors on iron status in a general Mediterranean population from Tarragona","volume":"89","author":"Aranda","year":"2010","journal-title":"Spain Ann Hematol"},{"key":"10.1016\/j.blre.2025.101319_bb0390","first-page":"e1","article-title":"Impact of Iron overload and Iron chelation with Deferasirox on outcomes of patients with severe aplastic Anemia after allogeneic hematopoietic stem cell transplantation","volume":"29(8):507","author":"Pan","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"12","key":"10.1016\/j.blre.2025.101319_bb0395","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/bmt.2009.88","article-title":"Effect of iron overload and iron-chelating therapy on allogeneic hematopoietic SCT in children","volume":"44","author":"Lee","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2025.101319_bb0400","first-page":"e1","article-title":"Iron chelation with Deferasirox suppresses the appearance of labile plasma Iron during conditioning chemotherapy prior to allogeneic stem cell transplantation","volume":"29(1):42","author":"Essmann","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"10.1016\/j.blre.2025.101319_bb0405","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/bmt.2012.94","article-title":"Pre-transplantation iron chelation in patients with MDS or acute leukemia and iron overload undergoing myeloablative Allo-SCT","volume":"48","author":"Armand","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"28","key":"10.1016\/j.blre.2025.101319_bb0410","doi-asserted-by":"crossref","first-page":"19543","DOI":"10.18632\/oncotarget.24646","article-title":"Total body irradiation and iron chelation treatment are associated with pancreatic injury following pediatric hematopoietic stem cell transplantation","volume":"9","author":"Maximova","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.blre.2025.101319_bb0415","first-page":"e1","article-title":"Iron chelation with Deferasirox increases Busulfan AUC during conditioning chemotherapy prior to allogeneic stem cell transplantation","volume":"28(2):115","author":"Essmann","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"5","key":"10.1016\/j.blre.2025.101319_bb0420","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1182\/blood.V87.5.2082.2082","article-title":"Marrow transplantation for patients with thalassemia: results in class 3 patients","volume":"87","author":"Lucarelli","year":"1996","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2025.101319_bb0425","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1097\/MPH.0000000000002328","article-title":"Efficacy and safety of Iron chelation therapy after allogeneic hematopoietic stem cell transplantation in pediatric thalassemia patients: a retrospective observational study","volume":"44","author":"Kupesiz","year":"2022","journal-title":"J Pediatr Hematol Oncol"},{"issue":"1","key":"10.1016\/j.blre.2025.101319_bb0430","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1080\/10428194.2016.1185787","article-title":"Potential anti-leukemic activity of iron chelation after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia","volume":"58","author":"Michallet","year":"2017","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"10.1016\/j.blre.2025.101319_bb0435","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1097\/TP.0b013e3181c42944","article-title":"The impact of desferrioxamine postallogeneic hematopoietic cell transplantation in relapse incidence and disease-free survival: a retrospective analysis","volume":"89","author":"Kaloyannidis","year":"2010","journal-title":"Transplantation"},{"key":"10.1016\/j.blre.2025.101319_bb0440","series-title":"Long-term transfusion Independence with Luspatercept versus Epoetin alfa in erythropoiesis-stimulating agent-naive","author":"Garcia-Manero","year":"2025"},{"issue":"9","key":"10.1016\/j.blre.2025.101319_bb0445","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(24)00203-5","article-title":"Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial","volume":"11","author":"Della Porta","year":"2024","journal-title":"Lancet Haematol"},{"issue":"3","key":"10.1016\/j.blre.2025.101319_bb0450","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/bjh.14602","article-title":"Iron chelation therapy in low risk myelodysplastic syndrome","volume":"177","author":"Killick","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2025.101319_bb0455","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/1477-7525-4-73","article-title":"The impact of iron overload and its treatment on quality of life: results from a literature review","volume":"4","author":"Abetz","year":"2006","journal-title":"Health Qual Life Outcomes"},{"issue":"1","key":"10.1016\/j.blre.2025.101319_bb0460","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12955-023-02221-y","article-title":"The impact of chelation compliance in health outcome and health related quality of life in thalassaemia patients: a systematic review","volume":"22","author":"Lee","year":"2024","journal-title":"Health Qual Life Outcomes"},{"issue":"10","key":"10.1016\/j.blre.2025.101319_bb0465","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1111\/j.1537-2995.2007.01398.x","article-title":"Clinical and economic burden of infused iron chelation therapy in the United States","volume":"47","author":"Payne","year":"2007","journal-title":"Transfusion"},{"issue":"4","key":"10.1016\/j.blre.2025.101319_bb0470","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1182\/blood.2023022501","article-title":"How I treat iron overload in adult MDS","volume":"145","author":"Leitch","year":"2025","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2025.101319_bb0475","doi-asserted-by":"crossref","first-page":"60","DOI":"10.6004\/jnccn.2017.0007","article-title":"Myelodysplastic syndromes, version 2.2017, NCCN clinical practice guidelines in oncology","volume":"15","author":"Greenberg","year":"2017","journal-title":"J Natl Compr Canc Netw"},{"issue":"4","key":"10.1016\/j.blre.2025.101319_bb0480","first-page":"300","article-title":"Intravenous chelation therapy during transplantation for thalassemia","volume":"80","author":"Gaziev","year":"1995","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.blre.2025.101319_bb0485","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1182\/blood.V90.3.994","article-title":"Phlebotomy to reduce iron overload in patients cured of thalassemia by bone marrow transplantation. Italian cooperative Group for Phlebotomy Treatment of transplanted thalassemia patients","volume":"90","author":"Angelucci","year":"1997","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.blre.2025.101319_bb0490","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/ejh.13222","article-title":"Update of the GIMEMA MDS0306 study: Deferasirox for lower risk transfusion-dependent patients with myelodysplastic syndromes","volume":"102","author":"Piciocchi","year":"2019","journal-title":"Eur J Haematol"},{"issue":"2","key":"10.1016\/j.blre.2025.101319_bb0495","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s00277-012-1594-z","article-title":"Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload","volume":"92","author":"Nolte","year":"2013","journal-title":"Ann Hematol"},{"issue":"11","key":"10.1016\/j.blre.2025.101319_bb0500","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.1080\/10428194.2017.1312385","article-title":"Erythroid response during iron chelation therapy in a cohort of patients affected by hematologic malignancies and aplastic anemia with transfusion requirement and iron overload: a FISM Italian multicenter retrospective study","volume":"58","author":"Messa","year":"2017","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"10.1016\/j.blre.2025.101319_bb0505","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/j.leukres.2013.07.006","article-title":"Hematological improvement during iron-chelation therapy in myelodysplastic syndromes: the experience of the \u201crete Ematologica Lombarda\u201d","volume":"37","author":"Molteni","year":"2013","journal-title":"Leuk Res"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X25000645?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X25000645?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T17:38:16Z","timestamp":1766079496000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X25000645"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":101,"alternative-id":["S0268960X25000645"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2025.101319","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Iron chelation therapy in myelodysplastic syndromes and allogeneic hematopoietic cell transplantation, a delicate balance","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2025.101319","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101319"}}